article
2021 bio/pharma financial round-up
European Pharmaceutical Review investigates the financial results of some of the top 10 pharma and biopharma companies worldwide.
List view / Grid view
Merck Sharp & Dohme
news
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
news
NICE requests more data on Keytruda for head and neck cancer treatment
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.
news
Results of Phase 2 study of lonafarnib in HDV infected patients published
20 July 2015 | By Victoria White
Results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection have been published...
news
Syndax and Merck to collaborate on immuno-oncology study evaluating entinostat in combination with Keytruda in lung cancer and melanoma
31 March 2015 | By Victoria White
Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat with Keytruda (pembrolizumab)...
article
Raw material identity verification in the pharmaceutical industry
Inspection of incoming raw materials is an essential step in the pharmaceutical industry to verify that the correct raw material which meets the quality specifications has been received. It will not only help to ensure that the final product is of best quality and minimise wasted time, material costs and…
article
High Content Screening for in vitro toxicity testing
20 June 2011 | By Willem G.E.J. Schoonen, Walter M.A. Westerink, Femke M. van de Water and G. Jean Horbach, Department of Toxicology & Drug Disposition, Merck Sharp & Dohme
The application of High Content Screening for in vitro toxicity testing is a relatively new approach in the preclinical research phase of drug development. A battery of tests have been developed for screening on general parameters such as cytotoxicity, while more dedicated assays are available with respect to the identification…
news
Next Generation Drug Development Summit: Imaging Biomarkers
9 November 2010 | By NG Online News
Senior executives from Eli Lilly, AstraZeneca, Johnson and Johnson & Pfizer to discuss the ROI for "non-surrogate" biomarkers, dose selection biomarkers and biomarkers of efficacy.
